[HTML][HTML] Efficacy and safety of bevacizumab combined with fluoropyrimidine monotherapy for unfit or older patients with metastatic colorectal cancer: a systematic …

C Pinto, L Antonuzzo, L Porcu, G Aprile… - Clinical Colorectal …, 2017 - Elsevier
Background Whether bevacizumab represents a feasible option for the first-line treatment of
unfit and elderly patients with metastatic colorectal cancer (mCRC) remains controversial …

SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients

EJ Kap, P Seibold, D Scherer… - … journal of cancer, 2016 - Wiley Online Library
Oxaliplatin is frequently used as part of a chemotherapeutic regimen with 5‐fluorouracil in
the treatment of colorectal cancer (CRC). The cellular availability of oxaliplatin is dependent …

TCF21 functions as a tumor suppressor in colorectal cancer through inactivation of PI3K/AKT signaling

Y Dai, H Duan, C Duan, H Zhu, R Zhou… - OncoTargets and …, 2017 - Taylor & Francis
Colorectal cancer (CRC) has become a major public health problem, ranking as the third
most common type of cancer. Our previous study has revealed that TCF21 is frequently …

Genetic variants in RPA1 associated with the response to oxaliplatin-based chemotherapy in colorectal cancer

S Li, K Xu, D Gu, L He, L **e, Z Chen, Z Fan… - Journal of …, 2019 - Springer
Abstract Background Oxaliplatin (L-OHP) is a commonly used first-line chemotherapy for
colorectal cancer. Genetic variants in nucleotide excision repair (NER) pathway genes may …

Screening and prognostic value of methylated septin9 and its association with clinicopathological and molecular characteristics in colorectal cancer

J Sun, J Xu, C Sun, M Zheng, Y Li, S Zhu… - Frontiers in Molecular …, 2021 - frontiersin.org
Screening of CRC continues to show poor compliance of endoscopy examination. The
detection of mSEPT9 in peripheral blood is among the safe and simple early screening …

Patterns of treatment sequences in chemotherapy and targeted biologics for metastatic colorectal cancer: findings from a large community-based cohort of elderly …

RC Parikh, XL Du, RO Morgan, DR Lairson - Drugs-real world outcomes, 2016 - Springer
Background Over the last decade, multiple chemotherapies/targeted biologics have been
approved for metastatic colorectal cancer (mCRC). However, evidence is limited with …

The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States

D Latremouille-Viau, J Chang, A Guerin… - Journal of medical …, 2017 - Taylor & Francis
Abstract Aims: Adverse events (AEs) associated with treatments for metastatic colorectal
cancer (mCRC) may compromise the course of treatment, impact quality-of-life, and increase …

Clinical characteristics and treatment propensity in elderly patients aged over 80 years with colorectal cancer

YH Jung, JY Kim, YN Jang, SH Yoo… - The Korean journal …, 2017 - pmc.ncbi.nlm.nih.gov
Background/Aims Elderly patients (≥ 80 years) with colorectal cancer (CRC) tend to avoid
active treatment at the time of diagnosis despite of recent advances in treatment. The aim of …

Cost-effectiveness of treatment sequences of chemotherapies and targeted biologics for elderly metastatic colorectal cancer patients

RC Parikh, XL Du, MO Robert, DR Lairson - Journal of Managed Care & …, 2017 - jmcp.org
BACKGROUND: Treatment patterns for metastatic colorectal cancer (mCRC) patients have
changed considerably over the last decade with the introduction of new chemotherapies and …

Updates in colorectal cancer stem cell research

CJ Li, X Zhang, GW Fan - Journal of cancer research and …, 2014 - journals.lww.com
Colorectal cancer (CRC) is one of the world most common malignant tumors, also is the
main disease, which cause tumor-associated death. Surgery and chemotherapy are the …